Johnson & Johnson has hit a milestone--with more than 200 collaborations formed through its Johnson & Johnson Innovation that was launched in 2013. The latest crop of 17 new collaborations with research institutions and healthcare companies brings with it at least 5 that clearly could help advance the state of med tech.
Swedish CRO TFS is working with local biotech LobSor Pharmaceuticals on a new treatment for Parkison's disease, agreeing to share the risks and potential rewards of the development process.
Chinese CRO WuXi PharmaTech is joining forces with the gene therapy experts at ReGenX Bio to hammer out a manufacturing process for the company's potential one-time treatments.
Under the "Make in India" initiative, India and the Netherlands signed a memorandum of understanding enabling Bharat Immunologicals and Biologicals, a public-sector biotech under India's department of biotechnology, to develop a measles and rubella vaccine with the assistance of the Netherlands' government-based Translational Vaccinology.
Johnson & Johnson today took the wraps off its latest collection of collaborations aimed at everything from setting up new "asset-centric" drug development operations with a partner in China to exploring ways to prevent Type 1 diabetes with investigators at Washington University. Its latest tally of 17 new deals and developments also includes a new Innovation hub in Sweden and brings its global total for its deal teams to more than 200 projects over two years running.
Nasdaq-listed Cellular Biomedicine Group, or CBMG, has clinical trial plans that include China for cancer vaccine CD40LGVAX bought from Blackbird Bio Finance.
South Korea's Celltrion and Samsung Bioepis are poised to gain new or expanded approval for biosimilars of some of the world's best-selling biological drugs, setting up a regulatory knowledge base on approvals and bringing commercial competition to major drugmakers not unlike that seen by small-molecule generics from India decades ago.
INC Research has started what it says is the industry's first site advocacy group, gathering study investigators to discuss how to improve speed and results in R&D.
Takeda Pharmaceutical has consolidated vaccine offices, signed a slew of alliances for discovery efforts and moved aggressively to refocus the company since Christophe Weber took over as CEO on April 1.
Celgene is handing over an $82.5 million upfront payment to snag an exclusive option on preclinical compounds at Lycera that promise to amp up the power of T cells being rededicated to fight cancer. In addition, Celgene is promising another $22.5 million in near-term payments to the University of Michigan spinoff.